Search global stocks & ETFs...Ctrl K

Learn Mode

CAPR - Capricor Therapeutics Inc

8

$28.79

-$1.02 (-3.422%)

At market close

$28.86

$0.07 (0.228%)

After Hours 5/15/26, 11:40 PM

Score

2.44/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

CAPR

Valuation Score

View as %

Stock Unlock

YTD

Max

Stock Profile

Market Cap

$1.67B

Industry

Biotechnology

EPS (TTM)

-$2.15

P/E (TTM)

0.00

Div & Yield

FCF Payout Ratio

P/S (TTM)

0.00

P/B

5.45

Diluted Shares

48.85M

Ex-Dividend

Next Earnings

08-10

Forward P/E

498.07

Payout Ratio

P/FCF (TTM)

0.00

FCF Yield

Earnings Yield

-6.30%

52 Week Range

Score Card

Explore Scores Tab

2.44

Bad

Capricor Therapeutics Inc has negative free cash flow of -81.54M, which means it is currently losing money. Also, it has negative operating cash flow of -69.81M, which means its not generating any profits on its operations.

Valuation Model

Key Score

3.00

Average

Management

4.00

Good

Growth

4.00

Good

Profitability

4.00

Good

Fin. Health

4.00

Good

Dividends

Analyst

4.00

Good

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

3 new filings were in the last 7 days

Filter Form Types

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-14 17:00:05

Form 10-Q

General form for quarterly financial reports under Section 13 or 15(d)

Filed on 2026-05-13 17:20:48

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-05-12 16:06:21

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-05-07 16:40:53

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-04 16:30:08

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-04 16:30:07

Form ARS

Unknown Form Type

Filed on 2026-04-10 17:17:53

Form DEF 14A

Also known as a 'definitive proxy statement', is a required filing when a shareholder vote is required

Filed on 2026-04-10 16:31:03

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-03 17:00:07

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-04-02 16:24:33

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-01 20:00:15

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-01 20:00:12

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-04-25

High:

$66.15

129.8%

Avg:

$55.76

93.7%

Low:

$43.43

50.9%

(% change is relative to the current stock price: $28.79)

Analyst Recommendations

Go to Analyst Tab

4.13

Good

20%

Strong Buy (3)

73%

Buy (11)

Hold (1)

Sell (0)

Strong Sell (0)

About

Website
https://capricor.com/
Address
10865 Road to the Cure, Suite 150, San Diego CALIFORNIA, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1133869

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. The company is headquartered in San Diego, California and currently employs 231 full-time employees. The company went IPO on 2002-06-04. The firm's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.

IPO Date

2002-06-04

Industry

Biotechnology

Total Employees

231

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences

CAPR - Capricor Therapeutics Inc

8

$28.79

-$1.02 (-3.422%)

$28.86

$0.07 (0.228%)

2.44/5

Stock Unlock

Stock Profile

Score Card

Bad

Insider Transactions

Market News

Form 4

Filed on 2026-05-14 17:00:05

Form 10-Q

Filed on 2026-05-13 17:20:48

Form 8-K

Filed on 2026-05-12 16:06:21

Form 8-K

Filed on 2026-05-07 16:40:53

Form 4

Filed on 2026-05-04 16:30:08

Form 4

Filed on 2026-05-04 16:30:07

Form ARS

Filed on 2026-04-10 17:17:53

Form DEF 14A

Filed on 2026-04-10 16:31:03

Form 4

Filed on 2026-04-03 17:00:07

Form 144

Filed on 2026-04-02 16:24:33

Form 4

Filed on 2026-04-01 20:00:15

Form 4

Filed on 2026-04-01 20:00:12

Financials

Price Targets

129.8%

93.7%

50.9%

Analyst Recommendations

About

Similar Stocks